放射性标记生长抑素受体拮抗剂与激动剂用于治疗难治性脑膜瘤患者的肽受体放射性核素治疗比较:PROMENADE 0期研究
这项前瞻性单中心开放标签0期研究纳入6例进展性标准治疗难治性脑膜瘤患者,比较[177Lu]Lu-DOTA-JR11(拮抗剂)与[177Lu]Lu-DOTATOC(激动剂)的治疗指数。结果显示[177Lu]Lu-DOTA-JR11使脑膜瘤吸收剂量更高、肿瘤与骨髓及肾脏吸收剂量比更优,疾病控制率达83%(95%CI 53%-100%),安全性可接受。
要点
- 单周期[177Lu]Lu-DOTA-JR11的脑膜瘤吸收剂量中位数11.5 Gy,高于[177Lu]Lu-DOTATOC的3.4 Gy。
- [177Lu]Lu-DOTA-JR11的肿瘤与骨髓吸收剂量比中位数高1.4倍,肿瘤与肾脏吸收剂量比高2.9倍。
- 疾病控制率83%(95%CI 53%-100%),未观察到4级或5级不良事件。
核心结论
- 单周期[177Lu]Lu-DOTA-JR11相比[177Lu]Lu-DOTATOC,在注射活度低1.4-2.1倍时脑膜瘤吸收剂量高2.2-5.7倍,治疗指数更有利。
- 初步疗效显示在标准治疗难治性脑膜瘤患者中疾病控制率高且安全性可接受。
- 作者认为需要在脑膜瘤患者中开展更大规模的使用[177Lu]Lu-DOTA-JR11的研究。
研究设计与样本
- 前瞻性、单中心、开放标签0期研究(NCT04997317),连续纳入6例患者(3男3女,平均年龄63.5岁)。
- 患者先接受6.9-7.3 GBq(标准注射活度)的[177Lu]Lu-DOTATOC,间隔10±1周后接受3.3-4.9 GBq(2 GBq/m2×体表面积)的[177Lu]Lu-DOTA-JR11。
- 共进行1个周期[177Lu]Lu-DOTATOC和2-3个周期[177Lu]Lu-DOTA-JR11治疗。
- 注射两种放射性药物后约24、48和168小时行定量SPECT/CT,采用三维分割方法计算脑膜瘤及器官吸收剂量和肿瘤与器官吸收剂量比。
主要发现
- 单周期脑膜瘤吸收剂量中位数:[177Lu]Lu-DOTATOC为3.4 Gy(范围0.8-10.2 Gy),[177Lu]Lu-DOTA-JR11为11.5 Gy(范围4.7-22.7 Gy)。
- 单周期骨髓吸收剂量中位数:[177Lu]Lu-DOTATOC为0.11 Gy(范围0.05-0.17 Gy),[177Lu]Lu-DOTA-JR11为0.29 Gy(范围0.16-0.39 Gy)。
- 单周期肾脏吸收剂量中位数:[177Lu]Lu-DOTATOC为2.7 Gy(范围1.3-5.3 Gy),[177Lu]Lu-DOTA-JR11为3.3 Gy(范围1.6-5.9 Gy)。
- [177Lu]Lu-DOTA-JR11的肿瘤与骨髓吸收剂量比中位数高1.4倍(范围0.9-1.9),肿瘤与肾脏吸收剂量比中位数高2.9倍(范围2.0-4.8)。
- 安全性:1周期[177Lu]Lu-DOTATOC后2例发生可逆性2级淋巴细胞减少;2-3周期[177Lu]Lu-DOTA-JR11后2例发生可逆性3级淋巴细胞减少,1例发生可逆性3级淋巴细胞减少和中性粒细胞减少;治疗开始后15个月或更长时间内未观察到4级或5级不良事件。
关键数值与推荐
- 单周期[177Lu]Lu-DOTA-JR11的脑膜瘤吸收剂量中位数11.5 Gy(范围4.7-22.7 Gy),[177Lu]Lu-DOTATOC为3.4 Gy(范围0.8-10.2 Gy)。
- [177Lu]Lu-DOTA-JR11的肿瘤与骨髓吸收剂量比中位数较[177Lu]Lu-DOTATOC高1.4倍(范围0.9-1.9)。
- [177Lu]Lu-DOTA-JR11的肿瘤与肾脏吸收剂量比中位数较[177Lu]Lu-DOTATOC高2.9倍(范围2.0-4.8)。
- 疾病控制率83%(95%CI 53%-100%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our primary aim was to compare the therapeutic index (tumor-to-bone marrow and tumor-to-kidney absorbed-dose ratios) of the new radiolabeled somatostatin receptor antagonist [177Lu]Lu-DOTA-JR11 with the established radiolabeled somatostatin receptor agonist [177Lu]Lu-DOTATOC in the same patients with progressive, standard therapy-refractory meningioma. Methods: In this prospective, single-center, open-label phase 0 study (NCT04997317), 6 consecutive patients were included: 3 men and 3 women (mean age, 63.5 y). Patients received 6.9-7.3 GBq (standard injected radioactivity) of [177Lu]Lu-DOTATOC followed by 3.3-4.9 GBq (2 GBq/m2 × body surface area) of [177Lu]Lu-DOTA-JR11 at an interval of 10 ± 1 wk. In total, 1 [177Lu]Lu-DOTATOC and 2-3 [177Lu]Lu-DOTA-JR11 treatment cycles were performed. Quantitative SPECT/CT was done at approximately 24, 48, and 168 h after injection of both radiopharmaceuticals to calculate meningioma and organ absorbed doses as well as tumor-to-organ absorbed-dose ratios (3-dimensional segmentation approach for meningioma, kidneys, liver, bone marrow, and spleen). Results: The median of the meningioma absorbed dose of 1 treatment cycle was 3.4 Gy (range, 0.8-10.2 Gy) for [177Lu]Lu-DOTATOC and 11.5 Gy (range, 4.7-22.7 Gy) for [177Lu]Lu-DOTA-JR11. The median bone marrow and kidney absorbed doses after 1 treatment cycle were 0.11 Gy (range, 0.05-0.17 Gy) and 2.7 Gy (range, 1.3-5.3 Gy) for [177Lu]Lu-DOTATOC and 0.29 Gy (range, 0.16-0.39 Gy) and 3.3 Gy (range, 1.6-5.9 Gy) for [177Lu]Lu-DOTA-JR11, resulting in a 1.4 (range, 0.9-1.9) times higher median tumor-to-bone marrow absorbed-dose ratio and a 2.9 (range, 2.0-4.8) times higher median tumor-to-kidney absorbed-dose ratio with [177Lu]Lu-DOTA-JR11. According to the Common Terminology Criteria for Adverse Events version 5.0, 2 patients developed reversible grade 2 lymphopenia after 1 cycle of [177Lu]Lu-DOTATOC. Afterward, 2 patients developed reversible grade 3 lymphopenia and 1 patient developed reversible grade 3 lymphopenia and neutropenia after 2-3 cycles of [177Lu]Lu-DOTA-JR11. No grade 4 or 5 adverse events were observed at 15 mo or more after the start of therapy. The disease control rate was 83% (95% CI, 53%-100%) at 12 mo or more after inclusion. Conclusion: Treatment with 1 cycle of [177Lu]Lu-DOTA-JR11 showed 2.2-5.7 times higher meningioma absorbed doses and a favorable therapeutic index compared with [177Lu]Lu-DOTATOC after injection of 1.4-2.1 times lower activities. The first efficacy results demonstrated a high disease control rate with an acceptable safety profile in the standard therapy for refractory meningioma patients. Therefore, larger studies with [177Lu]Lu-DOTA-JR11 are warranted in meningioma patients.
引用
- Eigler C, McDougall L, Bauman A, et al. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study. J Nucl Med. 2024. PMID: 38423782. doi:10.2967/jnumed.123.266817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。